Bruker Corporation (BRKR) Sets New 12-Month High at $30.77
Bruker Corporation (NASDAQ:BRKR) hit a new 52-week high on Thursday . The company traded as high as $30.77 and last traded at $30.77, with a volume of 80,717 shares trading hands. The stock had previously closed at $30.61.
A number of equities research analysts recently weighed in on BRKR shares. Zacks Investment Research raised Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research report on Thursday, July 6th. BidaskClub raised Bruker Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. Barclays PLC reaffirmed an “equal weight” rating and set a $30.00 price objective (up previously from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Cowen and Company reaffirmed a “hold” rating and set a $29.00 price objective on shares of Bruker Corporation in a research report on Friday, July 14th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $24.00 price objective on shares of Bruker Corporation in a research report on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $26.70.
The firm has a market capitalization of $4.88 billion, a P/E ratio of 30.67 and a beta of 1.09. The company’s 50 day moving average price is $29.53 and its 200-day moving average price is $27.29.
Bruker Corporation (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The business had revenue of $414.90 million during the quarter, compared to analysts’ expectations of $384.75 million. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 EPS. On average, equities analysts predict that Bruker Corporation will post $1.12 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 22nd. Stockholders of record on Tuesday, September 5th were given a dividend of $0.04 per share. The ex-dividend date was Thursday, August 31st. This represents a $0.16 annualized dividend and a dividend yield of 0.52%. Bruker Corporation’s dividend payout ratio is currently 16.00%.
In other news, VP Mark Munch sold 21,061 shares of the company’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the transaction, the vice president now directly owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Frank H. Laukien acquired 2,335 shares of the stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $27.39 per share, with a total value of $63,955.65. Following the completion of the transaction, the chief executive officer now owns 37,791,386 shares in the company, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. Corporate insiders own 35.20% of the company’s stock.
Several large investors have recently added to or reduced their stakes in BRKR. Acrospire Investment Management LLC boosted its position in shares of Bruker Corporation by 496.1% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock worth $110,000 after acquiring an additional 3,185 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Bruker Corporation during the 2nd quarter worth about $111,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Bruker Corporation by 11.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after acquiring an additional 467 shares in the last quarter. Smithfield Trust Co. acquired a new position in shares of Bruker Corporation during the 2nd quarter worth about $138,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Bruker Corporation by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after acquiring an additional 331 shares in the last quarter. 65.42% of the stock is owned by institutional investors and hedge funds.
About Bruker Corporation
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.